Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT and Timing in Combination With EGFR-TKI for Stage IV NSCLC
NCT03258671Unknown
- Sponsor
- Lubing Biotechnology
- Start
- Oct 2017
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Lubing Biotechnology. Primary endpoints: Therapeutic efficacy of EGFR-TKI and concurrent/concomitant local RT, Overall survival up to 5 years and 1 more. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03258671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258671.